TY - JOUR
T1 - Clinical trials of antiangiogenic agents
AU - Twardowski, Przemyslaw
AU - Gradishar, William J.
PY - 1997/1/1
Y1 - 1997/1/1
N2 - Acquisition of new blood vessels is a required step in malignant transformation, tumor growth, and metastasis. Inhibition of angiogenesis is one of the most promising new strategies for the treatment of malignant neoplasms. In recent years, several antiangiogenic compounds, including TNP-470, matrix metalloproteinase inhibitors, carboxyamidotriazole, and tecogalan sodium, have entered clinical trials. In this we review, we look at the results of early clinical trials of these agents and discuss the new angiogenesis inhibitors in preclinical development.
AB - Acquisition of new blood vessels is a required step in malignant transformation, tumor growth, and metastasis. Inhibition of angiogenesis is one of the most promising new strategies for the treatment of malignant neoplasms. In recent years, several antiangiogenic compounds, including TNP-470, matrix metalloproteinase inhibitors, carboxyamidotriazole, and tecogalan sodium, have entered clinical trials. In this we review, we look at the results of early clinical trials of these agents and discuss the new angiogenesis inhibitors in preclinical development.
UR - http://www.scopus.com/inward/record.url?scp=0030772175&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030772175&partnerID=8YFLogxK
U2 - 10.1097/00001622-199711000-00015
DO - 10.1097/00001622-199711000-00015
M3 - Review article
C2 - 9370081
AN - SCOPUS:0030772175
SN - 1040-8746
VL - 9
SP - 584
EP - 589
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 6
ER -
